Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 peptide vaccination with IDO and survivin peptides plus temozolomide and immune adjuvants in malignant melanoma
2011-004577-91Phase 2Terminated
- Sponsor
- National Center for Cancer Immune Therapy
- Start
- Dec 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IO103 acetate and temozolomide in melanoma, sponsored by National Center for Cancer Immune Therapy. Started Dec 2011; status: terminated.
02
Drugs
IO103 acetatetemozolomide
03
Conditions
melanoma
Beyond the preview
Go deeper on 2011-004577-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004577-91.